跳至主要内容
临床试验/NCT00467766
NCT00467766已完成不适用

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

Pfizer5 个研究点 分布在 3 个国家目标入组 300 人开始时间: 1999年7月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
300
试验地点
5
主要终点
Caregiver: Changes in depression, measured with the Beck Depression Inventory

研究概览

简要总结

A unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug treatment for Alzheimer's disease? Is the added value of psychosocial support the same in all 3 countries?

详细描述

This study is a single-blind prospective randomized trial with 150 patient/caregiver pairs (50 in each country). Eligibility criteria at baseline require that the primary caregiver is the spouse of the patient; the patient must have a diagnosis of AD, be in the in mild to moderate stage of dementia, be living with the caregiver, and be willing to take Donepezil (Aricept). These participants were randomly assigned to one of two groups: in one group, the intervention consists of drug treatment for the patient plus psychosocial intervention for the caregiver; in the other group the intervention consists solely of drug treatment for the patient.

The intervention for the caregiver consists of 5 scheduled individual and family counseling sessions within 3 months of baseline, and unlimited consultations on request. Assessments were conducted every 3 months for the first year and every 6 months for a second year. There are 3 sources of data: an interview of the caregiver by an independent rater, an assessment of the patient, and a count of the amount of medication used. Thus we will be able to assess the effect of adding counseling to medication for the caregiver, for the patient, and on compliance with medication use.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals diagnosed with mild to moderate stage Alzheimer's disease and their spouse caregivers

排除标准

  • Severe psychological or physical illness
  • Unwillingness by either spouse to participate in all aspects of the study

结局指标

主要结局

Caregiver: Changes in depression, measured with the Beck Depression Inventory

时间窗: every 3 months for the first year, and every 6 months for the second year

Caregiver: Changes in social support satisfaction, measured with the Stokes Social Network Scale

时间窗: every 3 months for the first year, and every 6 months for the second year

Patient: Changes in cognition measured by ADAS-cog

时间窗: every 3 months for the first year, and every 6 months for the second year

Patient: Changes in abilities with activities of daily living measured by ADCS-ADL

时间窗: every 3 months for the first year, and every 6 months for the second year

次要结局

  • Caregiver: Changes in reactions to patient behavior, physical health, family conflict and sense of mastery(every 3 months for the first year, and every 6 months for the second year)
  • Patient: Time to nursing home placement

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (5)

Loading locations...

相似试验